Reference
Karakuleli G, et al. Cost-Effectiveness of Ruxolitinib for Patients with Myelofibrosis: a Review of the Literature. 26th Congress of the European Haematology Association : abstr. PB1750, 9 Jun 2021. Available from: URL: https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324421/gizem.karakuleli.cost-effectiveness.of.ruxolitinib.for.patients.with.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Aot_id%3D25575%2Amarker%3D1287%2Afeatured%3D17286
Rights and permissions
About this article
Cite this article
Ruxolitinib cost effective for treatment of myelofibrosis. PharmacoEcon Outcomes News 884, 26 (2021). https://doi.org/10.1007/s40274-021-7933-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7933-3